VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | New approaches for AML patients who are not candidates for intensive therapy

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses novel treatment approached for patients with acute myeloid leukemia (AML) who are not candidates for intensive therapy. Dr de Botton highlights data on IDH2 inhibitors and on the IDH1 inhibitor olutasidenib, and comments on the need for more Phase II trials in this patient population. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter